Global Tissue Diagnostics Market: Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2016-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Tissue Diagnostics Market By Products (Instruments, Consumables) By Technology (Immunohistochemistry (IHC), Special Staining, In-Situ Hybridization (ISH), Digital Pathology and Workflow), By Application (Breast Cancer, Prostate Cancer, Lymphoma Cancer, Gastric Cancer, Non-Small Cell Lung Cancer), By Geography (Latin America, North America, Asia- Pacific, Middle East & Africa and Europe)

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The tissue diagnostics market is estimated to be valued at USD 19,907.1 Million in 2021, and it is expanded to grow at a significant CAGR of 9.5% over 2022-2028. An increase in the burden of disease among the population leads to a growing number of anatomic pathology tests requests to hospitals and independent laboratories etc. This is expected to boost the market for anatomic pathology services. In order to achieve sustainable development goals, access to high-quality and timely pathology and laboratory services is needed, and certain non-communicable diseases cannot be diagnosed only based on physical examination of clinical pathology. Hence, the number of test requests for anatomic pathology is increasing. According to the 2016 status report on “In Vitro Diagnostic Testing in Medical Practice,” the volume of laboratory testing is driven by clinical demand, and 66% of clinical decisions in the U.S. and Germany are based on anatomic pathology testing. Pathology and laboratory medicine comprise a mere 2.3% of the total healthcare spending. Despite this, pathology services are estimated to impact 70% -80% of the healthcare decisions. The pathology industry has started focusing on anatomic pathology due to industry fragmentation, high skilled nature of anatomic pathology services, and substantial historical growth in demand for anatomic pathology services despite payments cuts. This provides an opportunity for manufacturers of anatomic pathology solutions to invest in the independent pathology laboratories because demand for pathology services. The anatomic pathology segment is expected to contribute the highest revenue share of 75.4 percent in the tissue diagnostics market in 2020, owing to the vastly increased prevalence of chronic diseases worldwide, where this technology is used chiefly in tissue diagnostics. Moreover, an increasing number of hospitals are providing laboratory outreach programs which are expected to drive the growth of the anatomic pathology market.

Recent Market Developments:

In March 2021, Agilent Technologies Inc. announced that it has entered into a definitive agreement to acquire Resolution Bioscience Inc., a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions. The acquisition complements and expands Agilent’s capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market.

In July 2021, BD (Becton, Dickinson and Company), a leading global medical technology company, announced it has acquired Tepha, Inc., a leading developer and manufacturer of a propriletary resorbable polymer technology.

Tissue Diagnostics Market

MARKET SUMMARY
-
9.5% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 9.5%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Tissue Diagnostics Market

  • The report on global tissue diagnostics market gives historical, current and future market sizes (US$ Bn) based on Products, Technology, application, end users and region.
  • Tissue Diagnostics Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Market Key Players
  • Thermo Fisher Scientific (US)
  • Agilent Technologies (US)
  • Abbott Laboratories (US)
  • Merck KGa(Germany)
  • QIAGEN (Netherlands)
Tissue Diagnostics Market

Dynamics

The global tissue diagnostics market is mainly driven by the increasing prevalence of cancer advancements in diagnostics. Moreover, hospital outreach and physicians’ labs increase the demand for anatomic pathology services. High cost and lack of penetration in developing economies and lack of health insurance act as growth restraints in the worldwide tissue diagnostics market.


North-America Got Significant Share

Tissue Diagnostics Market

North America had the highest revenue share in the global tissue diagnostics market in 2021, accounting for USD 10,376.3 Mn, owing to the availability of favorable reimbursement scenarios for pathology diagnostic tests coupled with rising healthcare expenditure. Asia Pacific is anticipated to grow with 10.2% CAGR over the forecast period to reach USD 6,183.2 mn.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Tissue Diagnostics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Enzo Life Sciences
  • Agilent technologies
  • Hoffmann-La Roche Ltd.
  • QIAGEN
  • Bio SB.
  • Abbott
  • Merck KGaA, Darmstadt.
  • Cell Signaling Technology, Inc.
  • Becton, Dickinson and Company.

Description

The tissue diagnostics market is estimated to be valued at USD 19,907.1 Million in 2021, and it is expanded to grow at a significant CAGR of 9.5% over 2022-2028. An increase in the burden of disease among the population leads to a growing number of anatomic pathology tests requests to hospitals and independent laboratories etc. This is expected to boost the market for anatomic pathology services. In order to achieve sustainable development goals, access to high-quality and timely pathology and laboratory services is needed, and certain non-communicable diseases cannot be diagnosed only based on physical examination of clinical pathology. Hence, the number of test requests for anatomic pathology is increasing. According to the 2016 status report on “In Vitro Diagnostic Testing in Medical Practice,” the volume of laboratory testing is driven by clinical demand, and 66% of clinical decisions in the U.S. and Germany are based on anatomic pathology testing. Pathology and laboratory medicine comprise a mere 2.3% of the total healthcare spending. Despite this, pathology services are estimated to impact 70% -80% of the healthcare decisions. The pathology industry has started focusing on anatomic pathology due to industry fragmentation, high skilled nature of anatomic pathology services, and substantial historical growth in demand for anatomic pathology services despite payments cuts. This provides an opportunity for manufacturers of anatomic pathology solutions to invest in the independent pathology laboratories because demand for pathology services. The anatomic pathology segment is expected to contribute the highest revenue share of 75.4 percent in the tissue diagnostics market in 2020, owing to the vastly increased prevalence of chronic diseases worldwide, where this technology is used chiefly in tissue diagnostics. Moreover, an increasing number of hospitals are providing laboratory outreach programs which are expected to drive the growth of the anatomic pathology market.

Recent Market Developments:

In March 2021, Agilent Technologies Inc. announced that it has entered into a definitive agreement to acquire Resolution Bioscience Inc., a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions. The acquisition complements and expands Agilent’s capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market.

In July 2021, BD (Becton, Dickinson and Company), a leading global medical technology company, announced it has acquired Tepha, Inc., a leading developer and manufacturer of a propriletary resorbable polymer technology.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX